6 results
Profiles of Antidiabetic Medications - AACE 2018 

#Antidiabetic #Medications #Profiles #SideEffects #Table #DecisionAid #Orals #DM2 #Diabetes
#Profiles #SideEffects ... #Table #DecisionAid ... #Orals #DM2 #Diabetes ... #Endocrinology ... #Pharmacology #Management
Comparison of anti-diabetic or anti-hyperglycemic agents

There are numerous anti-hyperglycemic agents available to manage Type 2 diabetes.
Each class of medications ... #pharmacology #pharmacotherapy ... #table #comparison ... #diabetes #endocrinology ... #treatment
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Type 2 Inpatient Medication ... #Mellitus #DM2 ... #pharmacology # ... comparison #table ... #endocrinology
GLP-1 Agonists

Adlyxin (Lixisenatide) Daily
Bydureon (Exenatide ER) Weekly 
Ozempic (Semaglutide) Weekly 
Trulicity (Dulaglutide) Weekly 
Victoza (Liraglutide) Daily
commonly used medications ... to treat Type 2 Diabetes ... GLP1 #Agonists #Pharmacology ... #Dosing #Diabetes ... #DM2 #Endocrinology
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
Receptor Agonists - Pharmacology ... Ozempic), or daily tablet ... Receptor #Agonists #Pharmacology ... #Summary #DM2 # ... diabetes #endocrinology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
semaglutide, the same medication ... drug to remain stable ... #semaglutide #Diabetes ... #Pharmacology # ... Endocrinology